Wikibooks

Radiation Oncology/RTOG Trials/0421

< Radiation Oncology‎ | RTOG Trials


RTOG 04-21 (Head & Neck)

  • Title: A Phase III Trial for Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and chemotherapy versus chemotherapy alone
  • Objective: To determine whether re-irradiation plus concurrent chemotherapy improves overall survival of patients with previously irradiated, non-metastatic, locally recurrent or new primary squamous cell carcinoma of the head and neck (SCCHN) as compared to conventional chemotherapy alone
  • Protocol: Randomize to
    • Arm 1: RT + CT (RT 60 Gy in 1.5 Gy/fx on weeks 1, 3, 5, 7) + (Cisplatin/paclitaxel on weeks 1, 3, 5, 7) + (G-CSF on weeks 2, 4, 6, 8)
    • Arm 2: CT alone (select cisplatin/5-FU or cisplatin/paclitaxel or cisplatin/docetaxel)
  • Eligibility:
    • Pathologically confirmed squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx, larynx, or recurrent neck metastases with unknown primary
    • Patients must not be candidates for surgical resection.
  • Enrollment Target: 240 patients
  • Activation: April 27, 2005
  • Closed: January 5, 2007 -- Closed due to poor accrual
Retrieved from "https://en.wikibooks.org/w/index.php?title=Radiation_Oncology/RTOG_Trials/0421&oldid=3349069"